MedTrace Logo

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

NCT06315608 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-08-23

No results posted yet for this study

Summary

The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months.

Conditions

Interventions

DRUG

MRG-001

MRG-001 is a clear liquid solution for subcutaneous injection

Sponsors & Collaborators

  • MedRegen LLC

    lead INDUSTRY

Principal Investigators

  • Ali R Ahmadi, MD PhD · MedRegen LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-01-01
Completion
2026-03-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06315608 on ClinicalTrials.gov